Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro - PubMed (original) (raw)
Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro
C E Weeks et al. J Interferon Res. 1994 Apr.
Abstract
The low-molecular-weight immunomodulator drug candidate, imiquimod (R-837), and its hydroxylated metabolite R-842, induce interferon-alpha (IFN-alpha) in human blood cells in vitro when tested in concentrations of 0.5 microgram/ml or more. The amounts of IFN-alpha found increased with time from 2-6 h of incubation up to 24-48 h, and were dependent on cell number and drug concentration. These two chemicals yielded more IFN-alpha in human peripheral blood mononuclear cell (PBMC) cultures than other known inducers tested in parallel. They also induced detectable amounts of interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor-alpha in human PBMC cultures in vitro.
Similar articles
- Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463.
Wagner TL, Horton VL, Carlson GL, Myhre PE, Gibson SJ, Imbertson LM, Tomai MA. Wagner TL, et al. Cytokine. 1997 Nov;9(11):837-45. doi: 10.1006/cyto.1997.0239. Cytokine. 1997. PMID: 9367544 - Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.
Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, Noelle RJ, Miller RL, Kedl RM, Fitzgerald-Bocarsly P, Tomai MA, Vasilakos JP. Gibson SJ, et al. Cell Immunol. 2002 Jul-Aug;218(1-2):74-86. doi: 10.1016/s0008-8749(02)00517-8. Cell Immunol. 2002. PMID: 12470615 - Cytokine induction in mice by the immunomodulator imiquimod.
Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA. Reiter MJ, et al. J Leukoc Biol. 1994 Feb;55(2):234-40. doi: 10.1002/jlb.55.2.234. J Leukoc Biol. 1994. PMID: 7507969 - Imiquimod applied topically: a novel immune response modifier and new class of drug.
Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Miller RL, et al. Int J Immunopharmacol. 1999 Jan;21(1):1-14. doi: 10.1016/s0192-0561(98)00068-x. Int J Immunopharmacol. 1999. PMID: 10411278 Review. - [Pharmacological and clinical profile of imiquimod (BESELNA CREAM 5%)].
Tsuda T, Imada K, Mizuguchi K. Tsuda T, et al. Nihon Yakurigaku Zasshi. 2008 Jul;132(1):55-63. doi: 10.1254/fpj.132.55. Nihon Yakurigaku Zasshi. 2008. PMID: 18622104 Review. Japanese. No abstract available.
Cited by
- Immunotherapy in Basal Cell Carcinoma.
Ungureanu L, Vasilovici AF, Halmágyi SR, Trufin II, Apostu AP, Prisecaru M, Șenilă SC. Ungureanu L, et al. J Clin Med. 2024 Sep 26;13(19):5730. doi: 10.3390/jcm13195730. J Clin Med. 2024. PMID: 39407789 Free PMC article. Review. - Pharmacotherapy for Keloids and Hypertrophic Scars.
Murakami T, Shigeki S. Murakami T, et al. Int J Mol Sci. 2024 Apr 25;25(9):4674. doi: 10.3390/ijms25094674. Int J Mol Sci. 2024. PMID: 38731893 Free PMC article. Review. - IRF7 and RNH1 are modifying factors of HIV-1 reservoirs: a genome-wide association analysis.
Zhang Z, Trypsteen W, Blaauw M, Chu X, Rutsaert S, Vandekerckhove L, van der Heijden W, Dos Santos JC, Xu CJ, Swertz MA, van der Ven A, Li Y. Zhang Z, et al. BMC Med. 2021 Nov 16;19(1):282. doi: 10.1186/s12916-021-02156-5. BMC Med. 2021. PMID: 34781942 Free PMC article. - TLR7 Activation of Macrophages by Imiquimod Inhibits HIV Infection through Modulation of Viral Entry Cellular Factors.
Meng FZ, Liu JB, Wang X, Wang P, Hu WH, Hou W, Ho WZ. Meng FZ, et al. Biology (Basel). 2021 Jul 13;10(7):661. doi: 10.3390/biology10070661. Biology (Basel). 2021. PMID: 34356516 Free PMC article. - Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod.
Rozenblit M, Hendrickx W, Heguy A, Chiriboga L, Loomis C, Ray K, Darvishian F, Egeblad M, Demaria S, Marincola FM, Bedognetti D, Adams S. Rozenblit M, et al. Sci Rep. 2019 Jun 12;9(1):8572. doi: 10.1038/s41598-019-42784-9. Sci Rep. 2019. PMID: 31189943 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources